2017
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research 2017, 23: 2565-2574. PMID: 27815356, PMCID: PMC5418113, DOI: 10.1158/1078-0432.ccr-16-2152.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalCell ProliferationDog DiseasesDogsFemaleHumansMast CellsMutationPhosphorylationProto-Oncogene Proteins c-kitConceptsMast cell tumorsSpontaneous mast cell tumoursMast cell numbersMast cell degranulationCutaneous mast cell numberKIT phosphorylationCell degranulationOpen-label clinical studyBiochemical adverse eventsAcceptable safety profileMetastatic lymph nodesPharmacokinetics/pharmacodynamics profileFuture clinical evaluationClin Cancer ResCell numberDose-dependent mannerObjective responseAdverse eventsLymph nodesMCT patientsClinical effectsClinical toxicityClinical benefitHuman clinical applicationsSafety profile
2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003, 9: 2755-68. PMID: 12855656.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDog DiseasesDogsDose-Response Relationship, DrugEnzyme InhibitorsFemaleIndolesInhibitory Concentration 50MaleModels, ChemicalMutationNeoplasmsProto-Oncogene Proteins c-kitPyrrolesReceptor Protein-Tyrosine KinasesReceptors, Vascular Endothelial Growth FactorTime FactorsTomography, X-Ray ComputedConceptsReceptor tyrosine kinase inhibitorsTyrosine kinase inhibitorsGrowth factor receptorKinase inhibitorsSpontaneous malignanciesSpontaneous tumorsSmall molecule receptor tyrosine kinase inhibitorPhase I dose-escalating studyDose-escalating studyMeasurable objective responseSimilarities of canineVascular endothelial growth factor receptorStandard treatment regimensFactor receptorPhase I trialEndothelial growth factor receptorOverall response rateSoft tissue sarcomasPlatelet-derived growth factor receptorMast cell tumorsVariety of cancersStable diseaseObjective responseOral therapyProgressive disease